Endocrine Abstracts

Background and aims: Microalbuminuria (MA) is not specific predictor of early stages of chronic kidney disease (CKD) in diabetes. We investigate several markers that might be useful in assessing early kidney damage in T1DM and T2DM patients additional to MA.Materials and methods: We examined 111 patients (T1DM/T2DM: 51/60) with AER<20 mg/l (n=80); <199 mg/l (n=18); ≥200 mg/l (n=13). Biomarkers of kidney damage (c...

Introduction: ADH-deficiency (central diabetes insipidus, ADH-D) is a rare disease, and data on worldwide and country-specific prevalence rates are scarce. ADH-D registries could provide valuable information on epidemiology, etiological distribution, treatment requirements and potentially serve as a guide for management decisions in clinical practice.Objectives: To assess the epidemiological data on ADH-D in Russian Registry for Central Diabetes Insipidu...

Background and aims: To evaluate the level of tubular and glomerular biomarkers of kidney injury as potential nephroprorotective effects of GLP-1R agonist (liraglutide) addition in type 1 diabetic patients compared to standard insulin therapy.Materials and methods: 12 T1DM patients with normo-(AER <20 mg/l, n=7) and microalbuminuria (AER<199 mg/l, n=5) with liraglutide 1.2 mg as add on to insulin for 6 month and 12 patients with...

Aim: To assess the association of the endothelial dysfunction (ED) parameters and the lipid-lowering response to atorvastatin therapy in patients with T2D with genetic markers of inflammation.Methods: We include 97 T2D patients with first prescribed atorvastatin 10–20 mg: M/F 26/71; mean age 57 years. After 12 month of statin therapy, patients had fasting lipid profiles and ED parameters repeated. For ED evaluation, we performed pulse wave analysis ...

Aim: To evaluate the effect of PPARG2 Pro12Ala, TNFα G(308)A and G(238)A, LIPC C(-514)T, ACE I/D, SLCO1B1 Val174Ala polymorphism on the response to statins therapy in patients with type 2 diabetes mellitus (T2DM).Methods: We consecutively recruited patients with type 2 DM requiring lipid-lowering therapy according to current guidelines. Patients were started on either atorvastatin 10 or 20 mg. After 12 month of st...

Background: Pituitary disease registries are major instruments of epidemiological and clinical data collection used worldwide.Objective: To assess the epidemiological and clinical characteristics of acromegaly in Russia according to Russian hypothalamic and pituitary tumor registryMaterial and methods: Database of the Russian hypothalamic and pituitary tumor registry, which includes data from 84 regions of the country, was used for...

BackgroundPituitary disease registries are major instruments of epidemiological and clinical data collection used worldwide.ObjectiveTo assess the data of pituitary tumor registry in Russia.Material and methodsPatient records, retrieved from online platform of the Registry.ResultsCurrently there are 9858 patients regis...